Oral rabies vaccination of arctic foxes (Alopex lagopus) with an attenuated vaccine.
Arctic foxes were immunized with the SAG1 oral rabies vaccine. The effectiveness was determined by the serological response and by the survival to a challenge dose of rabies virus from an Alaskan fox. Vaccine virus was isolated from saliva 1 h after the liquid vaccine was placed directly into the mouth but not subsequently (tested up to 1 week postvaccination). Two weeks after vaccination, protective antibody levels were present in all foxes and all vaccinated foxes survived challenge at 9 weeks postvaccination. At 26 weeks postvaccination (17 weeks postchallenge) all but one fox had detectable antibody levels. Neural tissue harvested from surviving foxes was negative for rabies virus by direct immunofluorescent testing. One of the foxes vaccinated with SAG1 seroconverted and survived challenge even though the titre of the vaccine used was almost 4 logs less than that used to vaccinate the other foxes. These results suggest that the avirulent SAG1 oral rabies vaccine is very effective in protecting arctic foxes.